/Medtronic%20Plc%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Valued at a market cap of $112.9 billion, Medtronic plc (MDT) develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients and currently generates revenues from four major segments, which are Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio, and Diabetes. It is expected to announce its fiscal 2025 Q3 earnings results before the market opens on Tuesday, Feb. 18.
Prior to this event, analysts expect the healthcare company to report a profit of $1.36 per share, up 4.6% from $1.30 per share in the year-ago quarter. The company has a promising trajectory of consistently beating Wall Street's earnings estimates in the last four quarters. In Q2, MDT’s EPS of $1.26 outpaced the forecasted figure by 1.6%.